Global brain ischemia market will be growing at the CAGR of 7.6% During 2022-2030

Market Highlights

Brain ischemia is a medical condition in which there is lack of oxygen supply to the brain. This is due to narrowing of blood vesicles  which is caused due to blood clot or other factors like cholesterol. Since   last few years global brain ischemia market has been growing  swiftly and is expected to grow at CAGR of 7.6% from 2022 to 2030. Due to increasing prevalence of cardiovascular diseases and other diseases which are affecting cardiovascular which is major factor that causes  brain ischemia. Beside this adoption of sedentary lifestyle by the people across the globe has provided fuel for the growth of this market.

Geographically, global ischemia market is segmented into four major regions, North America, Europe, Asia Pacific plus Middle East and Africa. The worth of this  market in 2016 was 1.43 billion and is expected to reach till 2023 billion by the end of 2023 by growing continuously at the CAGR of 7.6 %. North America contribute the highest share in the brain ischemic market. Due to increasing number of diabetic, obese and aging population in North America are  major driving factor for the growth of this . Among all regions, ischemia’s market in Asia Pacific is the fastest growing market.  . Due to a huge population and increasing prevalence of diseases like sickle cell anemia and diabetes in this region all these together has served to a  platform for the growth of the market here.

Segmentation:

Global brain ischemia market is segmented on the basis of diagnosis which includes   MRI, CT, ultrasound, angiography and other. The market is also segmented on  the basis of treatment which includes  angioplasty, drug treatment and other. Drug treatment is sub segmented into anticoagulation therapy, antiplatelet and other. Anticoagulation therapy is further sub segmented into heparin and warfarin. Antiplatelet therapy is further sub segmented as aspirin and other. On the basis of end user the market is  segmented as hospital, clinics and other.

Key player  in  the global brain ischemia market are Bayer AG (Germany), H. Lundbeck A/S (Denmark), Bristol-Myers Squibb Company (US), Boehringer Ingelheim GmbH (Germany), ThromboGenics NV (Belgium), Vernalis Plc (UK), Neurotec Pharma SL (Spain), Johnson and Johnson (US), Covidien Plc (Ireland), Stryker Corporation (US), Abbott Laboratories (US), Penumbra, Inc. (US), Philips Healthcare (Netherland), Hitachi Ltd. (Japan), GE Healthcare (UK) and  Siemens Healthcare (US).

Due to increasing prevalence of many disease which causes  brain ischemia; all these have  attracted many multinational companies to develop their market in the global brain ischemia market.  Companies are using the  trend of strategic alliance and acquisition to gain a high position and minimize competition in the market

Bristol-Myers Squibb International which is headquartered in US; it  s working on the trials of  CV006-004, Acute Viprinex™ which are used for the treatment of brain ischemia.A/S has presented a new effective and safe data for desmoteplase which is an thrombolytic drug used for the treatment of acute ischemic stroke. It has received fast-track designation from the U.S. Food and Drug Administration (FDA) for the treatment of acute ischemic stroke.

Stryker Corporation’s new drug “Trevo® Retriever” has show a remarkable results when used in the treatment of brain ischemia. This drug is the declared as a front-line treatment to reduce disability in ischemic stroke since last 20 years.

Penumbra, Inc. which is a medical device manufacturing company  has launched the new MAX™ system reperfusion catheters for the treatment of acute ischemic stroke patients.

Boehringer Ingelheim GmbH a German headquartered company that has introduce Pradaxa® (dabigatran etexilate) an anticoagulant drug for the treatment of brain ischemia.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Brain Ischemia Market Research Report